The effectiveness of any drug supply systems in providing a trustworthy supply of essential drugs is a critical issue. To evaluate this effectiveness, it is necessary to watch over the status of the essential medicines in any country impartially and continuously. Some countries and also the World Health Organization (WHO) have codified a list of minimum medicines needed for a basic health care system and published them in assortments as a list of essential medicines. The aim of this study was to give an evaluation of the shortages status in Iran and identify the strengths and weaknesses of policies made in Ministry of Health during the years 2005 to 2008 in providing the essential drugs based on the WHO list of essential medicines.
Introduction
The effectiveness of drug supply systems in providing a reliable and trustworthy supply of essential medicines is a critical issue among different countries .The evaluation of the supply system of a country can be monitored via accessing the availability of essential medicines impartially and continuously. Drug shortages can frustrate the drug therapy process. Shortages can result in increased medical expenditures by increasing the probability of medical complications due to the lack of an appropriate therapy available at the proper time. Shortages can also result in more wasted time spent to of months in which a drug had faced the absolute shortage was counted. WHO has published a model list of essential medicines (2). To evaluate the importance of drug shortages of 13-Aban pharmacy, counted items were re-assorted on the basis of WHO essential medicines and the results of this assessment were compared with the results of original counts.
Results and Discussion
In this project, the shortage reports of the central purchasing unit in 13-Aban pharmacy dated between 2005 and 2008 were analyzed. The quantitative and qualitative overview of the data was done by the use of Iranian National Drug List (NDL) and WHO model list of essential medicines respectively (3).
As it is presented in Table 1 , the qualitative count of drug shortages shows 146 items affected with shortages during the years [2005] [2006] [2007] [2008] . Some of these items like fibrinolysin (ointment), lidocaine (1% vial) and carmustine (100 mg vial) had been cumulatively unavailable for more than one year. Comparing the items of this table with WHO list of essential medicines shows that 35 of 146 drug items were among essential pharmaceuticals. During these three years, antiinfective and antineoplastic medicines with 22 and 18 items respectively, had the highest shortages among the pharmaceuticals. Some broad spectrum antibiotics like Imipenem/ cilastatin (500 mg vial) and piperacillin/ tazobactam (2.25 and 4.5 mg vials) were among these medicines.
Because of the retrospective nature of this investigation, we encountered the following problems; I: All shortage reports of 13-Aban pharmacy are kept in paper sheet files and therefore, transforming data to Excel format was time consuming and tedious. II: Another problem was the missing of data sheets in archives. III: The shortages were reported when the manager realized that they are critical and therefore, it did not follow a definitive chronological.
Furthermore, 13-Aban is a community pharmacy and does not dispense all pharmaceuticals. Some of the pharmaceuticals like vaccines for routine immunization, narcotics and antivenins are not distributed in this attain drugs (1).
In Iran, we have faced with a significant incidence of drug shortages. These shortages have been reflected in 13-Aban pharmacy shortage reports. Tehran University of medical sciences, college of pharmacy, established seven community pharmacies in 1980s for its educational purposes that now are the major suppliers of medicine in Tehran, the capital of the country. These pharmacies have contracts with all main Iranian health insurance companies and they fill about thirty-five hundred prescriptions per day. Moreover, these pharmacies have an important role in the management of shortages since their establishment. In the case of shortages occurrence, distribution is usually centralized in these pharmacies to overcome insufficient supplies. Therefore, shortage reports of 13-Aban pharmacy are an alarm for the Ministry of Health (MOH) to be cautious about the shortages throughout the country.
With the above background, it is obvious that the shortage reports of 13-Aban pharmacy contain important information on the availability of medicines in the country. Analyzing these reports was the aim of this research project which can give clues about the status, strengths and weaknesses of Iran National Drug Policy (NDP) from March 2005 to 2008.
Experimental
Shortage data from 2005 to 2008 were collected from the central purchasing unit of 13-Aban pharmacy. Drugs were listed in shortage reports after the order of pharmacy to purchase from wholesaler failed for at least three times. Drug shortages were identified by buying staff and were reported under the supervision of a pharmacist who was the manager of the central purchasing unit. The shortage reports did not follow a definite chronological pattern and they were reported only when the pharmacist realized that there are critical. In this study, these reports were assorted monthly and more evaluation was done by quantitative and qualitative count of their items. In quantitative count of drugs, numbers of drugs which were affected by the shortages during some days or all days of a month were counted. Additionally, the number Gold sodium thiomalate, injection, 25 mg/0.5 mL 5
Gold sodium thiomalate, injection, 50 mg/0.5 mL 5
Penicillamine, capsule, 250 mg 6
Antidotes and Other Substances Used In Poisonings Methylene blue, injection, 100 mg/10 mL 6
Anticonvulsants/Antiepileptics
Diazepam suppository, 5mg 6
Ethosuximide, syrup, 250 mg/5 mL 9
Gabapentin, capsule, 100 mg 8
Gabapentin, capsule, 300 mg 6
Gabapentin, capsule, 400 mg 7
Phenobarbital, injection, 200 mg/mL 5
Anti-Infective Medicines
Amphotericin B, injection, 50 mg 8
Chloramphenicol, capsule, 250 mg 6
Chloramphenicol, suspension 150 mg/ 5 mL 9
Furazolidone, tablet, 100 mg 5
Imipenem and Cilastatin, injection, 500 mg Imipenem, 500 mg Cilastatin 6
Isoniazid, tablet, 300 mg 6
Levamisole, syrup, 40 mg/ 5 mL 6
Metronidazole, vaginal gel, 0.75% 10 Nafcillin, injection, 1 g/vial 7
Nitrofurantoin, tablet, 100 mg 7
Nystatin, ointment, 10,000,000 units/100 g 4 Tobramycin, injection, 40 mg/ mL (2 mL) 5
Zidovudine, capsule,100 mg 10 Omnipaque, vial 300 mg I/mL (10 mL) 5
Omnipaque, vial 240 mg I/ mL (10 mL) 4
Omnipaque, vial 240 mg I/mL (100 mL) 4
Omnipaque, vial 300 mg I/ mL (20 mL) 4
Gastrointestinal Medicines Estrogens (Conjugated/ Equine) (Premarin ®), injection, 25 mg/5 mL 7
Gonadorelin (Stimu-LH®), for injection, 0.1 mg 6
Protirelin (Stimu-TSH®), injection, 0.2 mg/mL 7 Gholami KH et al. / IJPR (2012), 11 (2): 565-572 pharmacy. Therefore, following the shortages of these items was not possible with this project. In the anti-parkinsonism medicines group, it can be observed that the four major drugs which are used in the treatment of these patients in Iran were affected by shortages for at least 6 months during these years, which have resulted in several switches between these drugs and therefore, a potential decrease in the patients' compliance may have occurred. Two widely used beta interferons, Betaferon® and Rebif®, which are prescribed for the multiple sclerosis patients have shown shortages for 4 and 3 months respectively. Any shortages in this group Tizanidine, tablet, 4 mg 4 * Alpha ointment is a burning ointment which has a natural source formula (Lawsonia inermis) and promotes healing and reduces scarring.
Table 1. (Continued) Drug Shortages from Educational Pharmacies in Tehran
of pharmaceuticals is especially important since the shortages can exert the stress on patients and it has been shown that Multiple sclerosis exacerbations may become more common after the stressful life events and a significant association between stress and MS relapses has been observed (4-6). There has not been a standard or a check list to determine the frequency of drug shortages. Therefore, shortages have different meanings for people with different perspectives. Most health care organizations consider the problems of the supply chain system as a major cause of drug shortages. These shortages can influence the patient care definitely, especially when the prescriber have to choose an alternative therapy (7). In this study, our focus was on supply issues. Databases used to compile the shortage reports were the back orders of the purchasing requests made by 13-Aban central purchasing unit. In accordance with these reports, quantitative and qualitative counts of shortages were done and the results of them are presented in Figure 1 and Table 1. A drug shortage usually does not have a single cause. It can be due to the manufacturing, marketing, economical, distribution and regulatory problems (8). The source of data in this project was limited to the central purchasing unit's back orders of 13-Aban pharmacy and therefore, the results could make conclusions on the signs and not the exact causes of shortages. Compiling other information has helped addressing the possible causes of these shortages. Comparing the chart of shortages with circumstantial events can be useful in finding some of the reasons for shortages. As it is shown in the Figure 1 , there are relationships among some of the chart's peaks with circumstantial events like United Nations (UN) Security Council bans and replacing the drug regulators. It seems possible that the regulation and enforcement problems be one of the reasons of the fluctuations in the drug market.
Many countries and also the WHO have codified a list of minimum medicines needed for a basic health care system and published them in assortments as a list of essential medicines. [2005] [2006] [2007] [2008] . It should be reminded that the research was carried out in a limited period of time and it does not consider the shortages before and after this period; although drug shortages out of this period of time may be considerable either. Our qualitative survey, however, showed that many of such shortages were not with regard to WHO essential medicines. The probable causes of Iranian drug shortages are possibly regulation and enforcement problems, continuous changes in FDO managers, and UN Security Council
